<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0087">
    <title>70 Tropheryma whipplei</title>
    <sect1 id="ch0087s0001">
      <title>70 Tropheryma whipplei</title>
      <anchor id="ch0087s000001a0001"/>
      <anchor id="ch0087s000000a0001"/>
      <para role="chapterAuthor"><phrase role="center">WALTER GEIßDÖRFER, ANNETTE MOTER, AND CHRISTIAN BOGDAN</phrase>
      </para>
      <para id="ch0087s000000p0001"><emphasis>Tropheryma whipplei</emphasis> is the agent of classical Whipple disease, an infection originally described by the American pathologist George Hoyt Whipple in 1907 as intestinal lipodystrophy (<link linkend="ch0087s000000li0001">1</link>–<link linkend="ch0087s000000li0003">3</link>). Since then, <emphasis>T. whipplei</emphasis> has been implicated in isolated infections of the central nervous system (CNS), heart valves, joints, eyes, and other organs. A remarkable amount of research over the past 30 years has yielded new insights into the epidemiology, biology, pathogenicity, and immunological control of this bacterium. However, early diagnosis of Whipple disease still remains a challenge, as witnessed by more than 50 case reports over the last three years. Reasons are the rarity of the disease, the diversity and nonspecificity of symptoms, the fastidious nature of the pathogen, and the lack of serological tests (<link linkend="ch0087s000000li0003">3</link>).</para>
      <sect2 id="ch0087s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0087s000001a0002"/>
        <anchor id="ch0087s000000a0002"/>
        <para id="ch0087s000000p0002"><emphasis>Tropheryma whipplei</emphasis> (the genus name is derived from “trophe” and “eryma,” the Greek words for “nourishment” and “barrier”) was identified in 1991 based on a 16S rRNA gene sequence amplified from a small bowel biopsy specimen (<link linkend="ch0087s000000li0004">4</link>, <link linkend="ch0087s000000li0005">5</link>). It has an exceptional status within the class of Gram-positive bacteria with high GC content (<emphasis>Actinobacteria</emphasis>, order <emphasis>Micrococcales</emphasis> [6]), owing to the low homology of its 16S rRNA gene sequence with that of other <emphasis>Actinobacteria</emphasis> (≤92%), its small genome (approximately 930 kbp), and its low GC content (46.3%) (<link linkend="ch0087s000000li0007">7</link>). A second, as-yet-unnamed <emphasis>Tropheryma</emphasis> species has been postulated from a significantly different 16S rRNA gene sequence amplified from the lung biopsy of a kidney transplant patient (<link linkend="ch0087s000000li0008">8</link>).</para>
      </sect2>
      <sect2 id="ch0087s0001s0002">
        <title>DESCRIPTION OF THE AGENT</title>
        <anchor id="ch0087s000001a0003"/>
        <anchor id="ch0087s000000a0003"/>
      </sect2>
    </sect1>
    <sect1 id="ch0087s0002">
      <title>Morphology</title>
      <anchor id="ch0087s000002a0001"/>
      <anchor id="ch0087s000000a0004"/>
      <para id="ch0087s000000p0003">Although<emphasis>T. whipplei</emphasis> is categorized as a Gram-positive actinobacterium, it stains poorly with the Gram stain and is negative with acid-fast staining. <emphasis>T. whipplei</emphasis> can be detected as intracellular clusters within phagocytic vacuoles or as extracellular bacteria (<link linkend="ch0087s000000li0009">9</link>). It forms slender rods that are visualizable with the periodic acid-Schiff (PAS) stain due to glycoproteins in its trilaminar envelope (<link linkend="ch0087s000000li0005">5</link>, <link linkend="ch0087s000000li0010">10</link>). After degradation of the <emphasis>T. whipplei</emphasis> bacteria by macrophages, remnants of the cell envelope remain as intracellular PAS-positive inclusions (<link linkend="ch0087s000000li0010">10</link>).</para>
    </sect1>
    <sect1 id="ch0087s0003">
      <title>Culture</title>
      <anchor id="ch0087s000003a0001"/>
      <anchor id="ch0087s000000a0005"/>
      <para id="ch0087s000000p0004">Since the first anecdotal report on the growth of<emphasis>T. whipplei</emphasis> in human macrophages deactivated by interleukin 4 (<link linkend="ch0087s000000li0011">11</link>) and the later-documented culture and isolation of <emphasis>T. whipplei</emphasis> in a human fibroblast cell line (<link linkend="ch0087s000000li0009">9</link>), <emphasis>T. whipplei</emphasis> strains have been isolated from a number of clinical specimen sources, including heart valves, blood, duodenal biopsy specimens (<link linkend="ch0087s000000li0012">12</link>), cerebrospinal fluid (CSF) (<link linkend="ch0087s000000li0007">7</link>), synovial fluid (<link linkend="ch0087s000000li0013">13</link>), vitreous fluid (<link linkend="ch0087s000000li0014">14</link>), skin (<link linkend="ch0087s000000li0015">15</link>), saliva (<link linkend="ch0087s000000li0016">16</link>), and stool (<link linkend="ch0087s000000li0017">17</link>). After genomic data revealed the absence of most genes necessary for amino acid synthesis, a cell-free culture method was developed using a medium supplemented with the missing amino acids and fetal calf serum (<link linkend="ch0087s000000li0018">18</link>). However, even optimized and standardized culture protocols of <emphasis>T. whipplei</emphasis> culture are insensitive, laborious, and slow (average time to detection of growth of 30 days [1]; doubling time of at least 28 hours [9, 18]). Therefore, they are not applicable as routine methods for the diagnosis of <emphasis>T. whipplei</emphasis> infection.</para>
    </sect1>
    <sect1 id="ch0087s0004">
      <title>Genome</title>
      <anchor id="ch0087s000004a0001"/>
      <anchor id="ch0087s000000a0006"/>
      <para id="ch0087s000000p0005">Data from two sequenced<emphasis>T. whipplei</emphasis> genomes reveal a small genome lacking key biosynthetic pathways. On the other hand, cell surface proteins are abundant, including a family of <emphasis>T. whipplei</emphasis>-specific surface proteins. Repetitive sequence elements may play a role in genetic and antigenic variation, suggesting host-dependent coevolution of <emphasis>T. whi</emphasis><emphasis>pplei</emphasis> (<link linkend="ch0087s000000li0007">7</link>).</para>
      <sect2 id="ch0087s0004s0001">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0087s000004a0002"/>
        <anchor id="ch0087s000000a0007"/>
        <para id="ch0087s000000p0006">Whipple disease is a rare condition, with an estimated annual incidence of 1 case per 100,000 to 1,000,000 (<link linkend="ch0087s000000li0001">1</link>). Infections with <emphasis>T. whipplei</emphasis> are mainly observed in middle-aged (average age, 56 years) white Caucasian males (73%) in Europe and North America (<link linkend="ch0087s000000li0001">1</link>, <link linkend="ch0087s000000li0019">19</link>), but also in Asia and Africa (<link linkend="ch0087s000000li0020">20</link>, <link linkend="ch0087s000000li0021">21</link>).</para>
        <para id="ch0087s000000p0007"><emphasis>T. whipplei</emphasis> DNA can be detected in wastewater from sewage plants, indicating an environmental occurrence of this bacterium (<link linkend="ch0087s000000li0022">22</link>, <link linkend="ch0087s000000li0023">23</link>). <emphasis>T. whipplei</emphasis> can be found in asymptomatic, healthy humans, suggesting that it can be a commensal bacterium and that human carriers may represent a reservoir (<link linkend="ch0087s000000li0001">1</link>). Genotyping studies suggest interhuman transmission of <emphasis>T. whipplei</emphasis> (probably via fecal-oral or oral-oral routes), as the same strains have predominantly been found within families or contact persons in France (<link linkend="ch0087s000000li0024">24</link>) and in rural villages in Senegal (<link linkend="ch0087s000000li0025">25</link>). Sequential colonization with two different strains of <emphasis>T. whipplei</emphasis> was observed in a sewage worker (<link linkend="ch0087s000000li0026">26</link>).</para>
        <anchor id="ch0087s000000a0008"/>
        <beginpage pagenum="1322"/>
      </sect2>
      <sect2 id="ch0087s0004s0002">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0087s000004a0003"/>
        <anchor id="ch0087s000000a0009"/>
      </sect2>
    </sect1>
    <sect1 id="ch0087s0005">
      <title>Pathogenesis and Immunology</title>
      <anchor id="ch0087s000005a0001"/>
      <anchor id="ch0087s000000a0010"/>
      <para id="ch0087s000000p0008">Local or systemic disease following<emphasis>T. whipplei</emphasis> infection is rare despite an abundance of this microbe in the environment and a high rate of human colonization (<link linkend="ch0087s000000li0027">27</link>, <link linkend="ch0087s000000li0028">28</link>). Thus, manifestations of clinical disease might require host immune predisposition. According to current models (<link linkend="ch0087s000000li0001">1</link>–<link linkend="ch0087s000000li0003">3</link>, <link linkend="ch0087s000000li0029">29</link>), <emphasis>T. whipplei</emphasis> is taken up orally, primarily in early childhood, leading to temporary asymptomatic carriage, and possibly self-limiting gastroenteritis, fever, or cough. Usually, a protective humoral and cellular immune response develops, resulting in the clearance of <emphasis>T. whipplei.</emphasis> In predisposed persons, <emphasis>T. whipplei</emphasis> may persist and spread systemically over a period of years, resulting in classical Whipple disease with infiltration of the lamina propria by alternatively activated macrophages (<anchor id="ch0087s000000a0011"/><link linkend="ch0087s000000a0012">Fig. 1</link> and 2), in which <emphasis>T. whipplei</emphasis> can survive by blocking the maturation of late acidic phagosomes to phagolysosomes (<link linkend="ch0087s000000li0030">30</link>, <link linkend="ch0087s000000li0031">31</link>). In addition to reduced production of interleukin 12 by dendritic cells and a shift of T-cell subsets from Th1 and Th17 cells toward Th2 and regulatory T cells (<link linkend="ch0087s000000li0032">32</link>), there is evidence for a reduced number of immunoglobulin-positive plasma cells and impaired secretion of immunoglobulins in duodenal lesions of Whipple disease patients (<link linkend="ch0087s000000li0033">33</link>). Findings like a higher frequency of HLA-DRB1*13 and DQB1*06 alleles in patients with Whipple disease (<link linkend="ch0087s000000li0034">34</link>) and loss-of-function mutation of the interferon regulatory factor 4 (IRF 4) gene found in a pedigree analysis (<link linkend="ch0087s000000li0035">35</link>) indicate a heterogeneous genetic predisposition of the human host. Characterization of bacterial factors involved in pathogenesis and of host factors predisposing to symptomatic <emphasis>T. whipplei</emphasis> infections are themes of current research.</para>
      <figure id="ch0087s000000f0001"><title><phrase role="figureLabel"><anchor id="ch0087s000000a0012"/><link linkend="ch0087s000000a0011">FIGURE 1</link></phrase> PAS staining of a duodenal biopsy specimen shows lymphangiectasia and massive infiltration of the lamina propria by strongly PAS-positive foamy macrophages containing <emphasis>T. whipplei.</emphasis> (Image kindly provided by Christoph Loddenkemper, Pathotres, Berlin, Germany.)</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0087f05.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0087s000000f0002"><title><phrase role="figureLabel"><anchor id="ch0087s000000a0013"/><link linkend="ch0087s000000a0044">FIGURE 2</link></phrase> FISH of a duodenal biopsy of an untreated Whipple disease patient using a <emphasis>T. whipplei</emphasis>-specific probe (<link linkend="ch0087s000000li0070">70</link>). The low-magnification image shows clusters of <emphasis>T. whipplei</emphasis> cells (yellow) against the slightly green tissue autofluorescent background. Host cell nuclei are stained blue with DAPI (4′,6-diamidino-2-phenylindole). (Inset) Single <emphasis>T. whipplei</emphasis> bacteria at a higher magnification.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0087f06.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
    </sect1>
    <sect1 id="ch0087s0006">
      <title>Classical (Systemic) Whipple Disease</title>
      <anchor id="ch0087s000006a0001"/>
      <anchor id="ch0087s000000a0014"/>
      <para id="ch0087s000000p0009">In classical Whipple disease, infection with<emphasis>T. whipplei</emphasis> probably occurs years before clinical manifestations point to the diagnosis. Chronic diarrhea, a leading symptom, can start mildly. Often, migratory arthralgias of large joints are prominent. After a prodromal phase, which can last for years, clinical manifestations worsen, with aggravated diarrhea, malabsorption, weight loss, abdominal pain, and lymphadenopathy, leading to a wasting syndrome. Nonspecific signs and symptoms like fever, night sweats, and asthenia may be present. Depending on the organ system(s) affected, a multitude of clinical findings can emerge (<anchor id="ch0087s000000a0015"/><link linkend="ch0087s000000a0019">Table 1</link>). Involvement of the CNS is a serious complication that occurs in approximately one-fifth of patients (<link linkend="ch0087s000000li0019">19</link>). The prognosis is unfavorable, because irreversible CNS damage may occur, and antibiotic treatment failure has been described (<link linkend="ch0087s000000li0036">36</link>). As CNS involvement may occur without symptoms, consideration may be given to CSF testing by nucleic acid amplification testing (NAAT) prior to antibiotic treatment in newly diagnosed Whipple disease. In case of a positive result, NAAT should be repeated from CSF as a follow-up after 6 to 12 months of antibiotic treatment to ensure clearance (<link linkend="ch0087s000000li0037">37</link>–<link linkend="ch0087s000000li0039">39</link>).</para>
    </sect1>
    <sect1 id="ch0087s0007">
      <title>Isolated Organ Manifestations</title>
      <anchor id="ch0087s000007a0001"/>
      <anchor id="ch0087s000000a0016"/>
      <sect2 id="ch0087s0007s0001">
        <title>Joints</title>
        <anchor id="ch0087s000007a0002"/>
        <anchor id="ch0087s000000a0017"/>
        <para id="ch0087s000000p0010">Together with diarrhea and malabsorption, joint involvement is a common symptom in classical Whipple disease and may even be the only clinical manifestation (<link linkend="ch0087s000000a0019">Table 1</link>). When it appears as migratory oligo- or polyarthritis, it is often misdiagnosed as seronegative rheumatoid arthritis (<link linkend="ch0087s000000li0040">40</link>). In cases of undiagnosed Whipple disease, treatment with corticosteroids or tumor necrosis factor antagonists may lead to clinical deterioration (<link linkend="ch0087s000000li0041">41</link>). Therefore, testing of duodenal biopsy specimens by PAS staining and NAAT for <emphasis>T. whipplei</emphasis> as well as examination of synovial fluid or synovial biopsy specimens by NAAT for <emphasis>T. whipplei</emphasis> has been suggested before the start of immunosuppressive therapy for presumptive autoimmune arthritis or in cases poorly responsive to immunosuppressive treatment (<link linkend="ch0087s000000li0042">42</link>, <link linkend="ch0087s000000li0043">43</link>). Two recent studies on 7 and on 18 patients, respectively, illustrate that (i) besides the predominantly affected large joints, metacarpophalangeal and interphalangeal joints can also be involved; (ii) erosive arthritis can be found; (iii) synovial fluid is the superior specimen for NAAT, rather than small bowel biopsy specimens; (iv) despite the absence of gastrointestinal symptoms, diagnosis can often be achieved by examination of small bowel biopsy specimens (if aspiration of synovial fluid is not possible); (v) diagnosis from small bowel biopsy specimens by NAAT is superior to PAS staining; and (vi) discontinuation of immunosuppressive therapy combined with antibiotic treatment regularly leads to complete remission (<link linkend="ch0087s000000li0044">44</link>, <link linkend="ch0087s000000li0045">45</link>).</para>
        <anchor id="ch0087s000000a0018"/>
        <beginpage pagenum="1323"/>
        <table id="ch0087s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0087s000000a0019"/><link linkend="ch0087s000000a0015">TABLE 1</link></phrase></emphasis> Symptoms and signs of <emphasis>T. whipplei</emphasis> infection
</title>
          
          <tgroup cols="3">
            <tbody>
              <row>
                <entry><phrase role="left">Organ system</phrase>
                </entry>
                <entry><phrase role="center">Sampling location or material</phrase>
                </entry>
                <entry><phrase role="center">Sign(s) and/or symptom(s)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">General condition</phrase>
                </entry>
                <entry/>
                <entry><phrase role="left">Weight loss, fever, impaired health condition</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Gastrointestinal tract</phrase>
                </entry>
                <entry><phrase role="left">Esophagus, stomach, duodenum, jejunum, ileum, cecum</phrase>
                </entry>
                <entry><phrase role="left">Acute and chronic diarrhea, abdominal pain, malabsorption</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">Stool</phrase>
                </entry>
                <entry><phrase role="left">Asymptomatic carrier; acute gastroenteritis</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">Saliva</phrase>
                </entry>
                <entry><phrase role="left">Asymptomatic carrier</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Joints and bones</phrase>
                </entry>
                <entry><phrase role="left">Synovial fluid, synovium or bone biopsy specimen</phrase>
                </entry>
                <entry><phrase role="left">Arthralgia, arthritis</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">CNS</phrase>
                </entry>
                <entry><phrase role="left">CSF, brain biopsy</phrase>
                </entry>
                <entry><phrase role="left">Cognitive changes, movement disorders, ophthalmoplegia, oculomasticatory myorhythmia, headache, dementia, depression, seizures</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Cardiovascular</phrase>
                </entry>
                <entry><phrase role="left">Resected heart valve, whole blood</phrase>
                </entry>
                <entry><phrase role="left">Infective endocarditis: vegetations on heart valves, symptoms and signs of valve stenosis or insufficiency</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">Pericardial effusion</phrase>
                </entry>
                <entry><phrase role="left">Pericarditis, myocarditis</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Skin</phrase>
                </entry>
                <entry><phrase role="left">Skin biopsy specimen</phrase>
                </entry>
                <entry><phrase role="left">Cutaneous pigmentation</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Eye</phrase>
                </entry>
                <entry><phrase role="left">Vitreous fluid</phrase>
                </entry>
                <entry><phrase role="left">Uveitis, retinitis, vision loss, eye floaters</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Lymphatic system</phrase>
                </entry>
                <entry><phrase role="left">Lymph node</phrase>
                </entry>
                <entry><phrase role="left">Lymphadenopathy</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Lung</phrase>
                </entry>
                <entry><phrase role="left">Bronchoalveolar lavage fluid, pleural effusion, lung biopsy specimen</phrase>
                </entry>
                <entry><phrase role="left">Acute pneumonia</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Kidney (rare)</phrase>
                </entry>
                <entry><phrase role="left">Kidney biopsy specimen</phrase>
                </entry>
                <entry><phrase role="left">Secondary amyloidosis</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
      </sect2>
      <sect2 id="ch0087s0007s0002">
        <title>CNS</title>
        <anchor id="ch0087s000007a0003"/>
        <anchor id="ch0087s000000a0020"/>
        <para id="ch0087s000000p0011">Nonspecific neurological and psychiatric manifestations can be the only pathological findings of<emphasis>T. whipplei</emphasis> infection, ranging from ocular movement disturbances (e.g., oculomasticatory myorhythmia), seizures, ataxia, and headache to psychiatric disorders such as depression, personality changes, dementia, or memory impairment. On magnetic resonance imaging or computed tomography scans, solitary or multiple enhancing lesions can be present, involving the temporal lobe, midbrain, hypothalamus, and thalamus regions (<link linkend="ch0087s000000li0046">46</link>). Diagnosis is often delayed and is made by NAAT for <emphasis>T. whipplei</emphasis> DNA in CSF or by histopathologic evaluation of brain biopsy specimens along with tissue-based NAAT for <emphasis>T. whipplei</emphasis> in cases of encephalitis with NAAT-negative results from CSF (<link linkend="ch0087s000000li0047">47</link>).</para>
      </sect2>
      <sect2 id="ch0087s0007s0003">
        <title>Eyes</title>
        <anchor id="ch0087s000007a0004"/>
        <anchor id="ch0087s000000a0021"/>
        <para id="ch0087s000000p0012">Two studies on Whipple disease with 696 and 113 patients revealed ocular involvement in 3% and 6% of the cases, respectively (<link linkend="ch0087s000000li0019">19</link>, <link linkend="ch0087s000000li0048">48</link>). Symptoms and signs may be nonspecific, occurring bi- or unilaterally and include mild vision loss or blurry vision, diplopia, eye floaters, and neuro-ophthalmic findings such as ophthalmoplegia, nystagmus, and papilledema (<link linkend="ch0087s000000li0049">49</link>, <link linkend="ch0087s000000li0050">50</link>). Characteristic ocular findings are intraocular inflammation (uveitis, retinitis, and endophthalmitis) or crystalline keratopathy. In most cases, diagnosis of the typically chronic and corticosteroid-resistant infection is made years after the onset of symptoms by NAAT of vitreous fluid. Although ocular involvement may be the only clinical finding of Whipple disease at the time of presentation (<link linkend="ch0087s000000li0049">49</link>, <link linkend="ch0087s000000li0050">50</link>), in general, ocular infection by <emphasis>T. whipplei</emphasis> points to classical Whipple disease and can therefore be diagnosed by evaluation of other tissues, e.g., small bowel biopsy specimens.</para>
      </sect2>
      <sect2 id="ch0087s0007s0004">
        <title>Endocarditis</title>
        <anchor id="ch0087s000007a0005"/>
        <anchor id="ch0087s000000a0022"/>
        <para id="ch0087s000000p0013">Endocarditis (<anchor id="ch0087s000000a0023"/><link linkend="ch0087s000000a0026">Fig. 3</link>) accounts for 9% and 6% of culture-negative endocarditis cases in France (Department Rhône-Alpes) (<link linkend="ch0087s000000li0051">51</link>) and Germany (<link linkend="ch0087s000000li0052">52</link>), respectively, and may occur as a complication of classical Whipple disease (6 of 113 cases [19]) or as a localized infection (14 of 16 cases [52]). This suggests that most patients with isolated <emphasis>T. whipplei</emphasis> endocarditis might not exhibit the putative immunodeficiency that predisposes patients to systemic Whipple disease. Heart valve vegetations are detected by echocardiography in 78% of cases. Arthralgias are a frequent (75%) clinical symptom, with fever present in only 39% of cases. Duke criteria are not helpful in establishing a definitive diagnosis of Whipple endocarditis (<link linkend="ch0087s000000li0051">51</link>, <link linkend="ch0087s000000li0052">52</link>). 16S rRNA gene NAAT followed by sequencing or <emphasis>T. whipplei</emphasis>-specific NAAT of resected heart valves is the diagnostic method of choice. NAAT of blood can be helpful, but it is not sensitive enough to exclude a diagnosis of Whipple endocarditis (<link linkend="ch0087s000000li0053">53</link>). NAAT of morning urine might be an option, as recently reported (<link linkend="ch0087s000000li0054">54</link>).</para>
      </sect2>
      <sect2 id="ch0087s0007s0005">
        <title>Immune Reconstitution Inflammatory Syndrome</title>
        <anchor id="ch0087s000007a0006"/>
        <anchor id="ch0087s000000a0024"/>
        <para id="ch0087s000000p0014">Immune reconstitution inflammatory syndrome (IRIS), which was first reported as a complication following treatment of Whipple disease in 2009 (<link linkend="ch0087s000000li0055">55</link>), has been diagnosed in up to 11% of treated patients. Prior immunosuppressive treatment (e.g., for suspected rheumatoid arthritis) is a risk factor for the development of IRIS. After initial clinical improvement, immune reaction to nonviable <emphasis>T. whipplei</emphasis> antigen(s) results in symptoms including fever, arthralgias, gastrointestinal symptoms, and skin irritation. NAATs typically remain negative in this situation. After exclusion of opportunistic infections, corticosteroid treatment may be effective (reference <link linkend="ch0087s000000li0056">56</link> and references therein).</para>
        <anchor id="ch0087s000000a0025"/>
        <beginpage pagenum="1324"/>
        <figure id="ch0087s000000f0003"><title><phrase role="figureLabel"><anchor id="ch0087s000000a0026"/><link linkend="ch0087s000000a0023">FIGURE 3</link></phrase> FISH of a heart valve section in a case of culture-negative endocarditis using a <emphasis>T. whipplei</emphasis>-specific probe (Cy3; orange) (<link linkend="ch0087s000000li0070">70</link>). The low-magnification image shows extensive areas with bacterial colonization (slightly orange glimmer) along with calcified tissue (bright yellow-green autofluorescence). Host cell nuclei are stained blue with DAPI. (Inset) Dense clusters of <emphasis>T. whipplei</emphasis> cells at a higher magnification (orange).</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0087f07.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0087s0007s0006">
        <title>Acute Gastroenteritis</title>
        <anchor id="ch0087s000007a0007"/>
        <anchor id="ch0087s000000a0027"/>
        <para id="ch0087s000000p0015">Diarrhea and abdominal pain are frequent symptoms in classical Whipple disease. Large quantities of<emphasis>T. whipplei</emphasis> DNA have been detected in stool samples from children with acute gastroenteritis (<link linkend="ch0087s000000li0057">57</link>). In a study of children aged ≤6 years, <emphasis>T. whipplei</emphasis> DNA was significantly more often detected in rectal swabs from children with diarrhea (22/555 [4%]) than without diarrhea (56/3,241 [1.7%]) (<link linkend="ch0087s000000li0058">58</link>). However, it remains unclear whether this unusual finding reflects causality or an accidental association.</para>
      </sect2>
      <sect2 id="ch0087s0007s0007">
        <title>Skin</title>
        <anchor id="ch0087s000007a0008"/>
        <anchor id="ch0087s000000a0028"/>
        <para id="ch0087s000000p0016">Manifestations like melanoderma, hyperkeratosis, peripheral edema, petechiae, and purpura may be present in late stages of the disease. Interestingly,<emphasis>T. whipplei</emphasis> DNA may be detected in skin biopsies of patients with Whipple disease, even in the absence of cutaneous symptoms (<link linkend="ch0087s000000li0015">15</link>). Highly sensitive NAATs may be diagnostic tools to test skin specimens for <emphasis>T. whipplei</emphasis> DNA, although negative PCR results do not exclude Whipple disease (<link linkend="ch0087s000000li0059">59</link>).</para>
      </sect2>
      <sect2 id="ch0087s0007s0008">
        <title>Lungs</title>
        <anchor id="ch0087s000007a0009"/>
        <anchor id="ch0087s000000a0029"/>
        <para id="ch0087s000000p0017">Pulmonary involvement (pleural effusion, pulmonary infiltration, and granulomatous mediastinal adenopathy) is estimated to occur in 30 to 40% of patients with classical Whipple disease (<link linkend="ch0087s000000li0048">48</link>). Interstitial lung disease with detection of <emphasis>T. whipplei</emphasis> in pulmonary parenchymal nodules has been reported in a few cases (<link linkend="ch0087s000000li0019">19</link>). The putative role of <emphasis>T. whipplei</emphasis> as a cause of acute pneumonia and the relevance of its more frequent detection in bronchoalveolar lavage specimens of HIV-positive than in HIV-negative individuals (13% versus 1%) need further investigation (reference <link linkend="ch0087s000000li0060">60</link> and references therein).</para>
      </sect2>
      <sect2 id="ch0087s0007s0009">
        <title>Kidneys, Urine</title>
        <anchor id="ch0087s000007a0010"/>
        <anchor id="ch0087s000000a0030"/>
        <para id="ch0087s000000p0018">Recently, infection of the kidneys of a Whipple disease patient was shown. Detection of<emphasis>T. whipplei</emphasis> bacteria by fluorescence <emphasis>in situ</emphasis> hybridization (FISH) and PAS staining techniques within the tubular lumens (i.e., in the primary urine) was suggestive of possible renal filtration of bacteria, offering the perspective that morning urine analysis could be a noninvasive method for the diagnosis of Whipple disease (<link linkend="ch0087s000000li0054">54</link>). It was suggested that a positive NAAT from urine sediment, in contrast to stool or saliva, may indicate infection rather than colonization. <emphasis>T. whipplei</emphasis> was detected in urine sediments by NAAT in 9 of 12 patients (<link linkend="ch0087s000000li0054">54</link>) and 10 of 13 patients (<link linkend="ch0087s000000li0061">61</link>) with classical Whipple disease and in one patient with isolated endocarditis, but not in control persons, including healthy carriers. Thus, urine sediment is a potential specimen to include in diagnostic workflows, although more data are needed for confirmation (<link linkend="ch0087s000000li0062">62</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0087s0008">
      <title>Healthy Carriers</title>
      <anchor id="ch0087s000008a0001"/>
      <anchor id="ch0087s000000a0031"/>
      <para id="ch0087s000000p0019"><emphasis>T. whipplei</emphasis> can be detected in stool, intestinal biopsy, gastric juice, saliva, and dental plaque of healthy individuals without clinical findings of Whipple disease. Although early reports may have overestimated the prevalence rate because of false-positive PCR results (<link linkend="ch0087s000000li0063">63</link>), colonization of asymptomatic adults is well established. In stool and saliva specimens, the estimated positivity rates are 4% and ≤1%, respectively (<link linkend="ch0087s000000li0027">27</link>, <link linkend="ch0087s000000li0028">28</link>). Higher positivity rates are found in humans with increased risks for acquisition of <emphasis>T. whipplei</emphasis> (e.g., sewage workers [28], people experiencing homelessness [64], and family members of Whipple disease patients [24]). The prevalence and bacterial loads of <emphasis>T. whipplei</emphasis> are much higher in stool (prevalence, 92%) and saliva (65%) from patients with classical Whipple disease than in specimens from patients with localized Whipple disease or carriers. Based on this finding, NAATs from stool and saliva have been described as a tool for noninvasive screening of patients for classical Whipple disease with a high negative predictive value (99%) (<link linkend="ch0087s000000li0015">15</link>, <link linkend="ch0087s000000li0027">27</link>). However, positive NAAT results from saliva and stool specimens do not prove infection, and negative NAAT results from saliva and stool specimens do not completely rule out infection. Very high prevalences of <emphasis>T. whipplei</emphasis> DNA have been reported in stool samples of young children from Senegal (75%) and Laos (48%) (<link linkend="ch0087s000000li0020">20</link>, <link linkend="ch0087s000000li0021">21</link>). As environmental specimens were largely negative for <emphasis>T. whipplei</emphasis> DNA and colonization with <emphasis>T. whipplei</emphasis> correlated with the exposure to human feces due to limited access to sanitary facilities and toilets, these findings most likely reflect a human reservoir of <emphasis>T. whipplei</emphasis> and early colonization due to fecal-oral transmission (<link linkend="ch0087s000000li0021">21</link>).</para>
      <sect2 id="ch0087s0008s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0087s000008a0002"/>
        <anchor id="ch0087s000000a0032"/>
        <para id="ch0087s000000p0020">Small bowel biopsy specimens should be examined by PAS staining whenever classical Whipple disease is suspected (<anchor id="ch0087s000000a0033"/><link linkend="ch0087s000000a0035">Fig. 4</link>). If results of PAS staining are unclear or negative and Whipple disease is still suspected, NAAT testing should be considered. To avoid sampling errors in cases with macroscopically unchanged mucosa or sparse or patchy prevalence of PAS stain-positive macrophages, at least five endoscopic biopsy specimens from the small bowel (distal duodenum and/or jejunum) should be evaluated by histology with hematoxylin-and-eosin and PAS staining. In the case of positive results, consideration should be given to testing CSF by NAAT to assess for CNS involvement. Alternative workflows comprising highly sensitive NAAT testing of noninvasive samples like stool, saliva (<link linkend="ch0087s000000li0059">59</link>), and urine specimens (<link linkend="ch0087s000000li0054">54</link>, <link linkend="ch0087s000000li0062">62</link>) have been suggested as first steps in the diagnosis of classical Whipple disease (<link linkend="ch0087s000000li0059">59</link>); positive NAAT in these samples alone is not sufficient for diagnosis of Whipple disease but should prompt invasive sampling. Further studies are needed to determine whether this approach is clinically useful. To test for isolated <emphasis>T. whipplei</emphasis> infection, a sample of the affected tissue should be examined by NAAT and histological methods, including PAS staining. When positive results are obtained, gastrointestinal and CNS involvement should be considered and appropriate diagnostic specimens evaluated, as clinically indicated.</para>
        <anchor id="ch0087s000000a0034"/>
        <beginpage pagenum="1325"/>
        <figure id="ch0087s000000f0004"><title><phrase role="figureLabel"><anchor id="ch0087s000000a0035"/><link linkend="ch0087s000000a0033">FIGURE 4</link></phrase> Hierarchical scheme for the diagnosis of Whipple disease. 1, positive PCR should be confirmed by 16S rRNA gene sequencing or a second specific PCR targeting a different <emphasis>T. whipplei</emphasis> gene sequence; 2, IHC and FISH are available only in specialized laboratories. (Modified from reference <link linkend="ch0087s000000li0003">3</link>.)</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0087f04.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0087s000000p0021">Samples for PAS staining, immunohistochemistry (IHC), or FISH analysis should be transported in fixation solution. For NAAT, samples are preferably not fixed (e.g., no formalin); naive tissue samples (in sterile physiological saline) can be transported at room temperature as long as the samples arrive in the diagnostic laboratory within 1 day. If assays cannot be done within 1 day, fresh samples can be stored for a few days at 4°C and long term at −80°C. For culture, fresh samples should be frozen at −80°C and transported on dry ice.</para>
      </sect2>
      <sect2 id="ch0087s0008s0002">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0087s000008a0003"/>
        <anchor id="ch0087s000000a0036"/>
      </sect2>
    </sect1>
    <sect1 id="ch0087s0009">
      <title>Microscopy</title>
      <anchor id="ch0087s000009a0001"/>
      <anchor id="ch0087s000000a0037"/>
      <sect2 id="ch0087s0009s0001">
        <title>PAS Staining</title>
        <anchor id="ch0087s000009a0002"/>
        <anchor id="ch0087s000000a0038"/>
        <para id="ch0087s000000p0022">PAS staining of biopsy specimens from the lower duodenum or jejunum typically shows an infiltration of the lamina propria with foamy macrophages containing PAS-positive, diastase-negative granular inclusions of intracellular or ingested bacteria with characteristic morphologic features of Whipple disease (<link linkend="ch0087s000000a0012">Fig. 1</link>). PAS staining can be positive due to infection with other agents (e.g., nontuberculous mycobacteria), but Whipple disease can be differentiated from other agents by alternative special stains. PAS staining can also be falsely negative as a consequence of low bacterial load (<link linkend="ch0087s000000li0065">65</link>). Therefore, if positive PAS results are not clearly due to <emphasis>T. whipplei</emphasis>, they should be confirmed by an independent and specific method (e.g., NAAT, IHC, or FISH). Similarly, despite a negative PAS result in cases where continuing clinical suspicion of Whipple disease exists, NAAT should be performed due to its high sensitivity to detect small quantities of <emphasis>T. whipplei</emphasis> (<link linkend="ch0087s000000li0001">1</link>, <link linkend="ch0087s000000li0003">3</link>, <link linkend="ch0087s000000li0045">45</link>) (<link linkend="ch0087s000000a0035">Fig. 4</link>).</para>
        <para id="ch0087s000000p0023">In patients without gastrointestinal manifestations, specimens from the clinically affected sites, e.g., explanted heart valves, lymph nodes, synovial tissue, CSF, or brain biopsy specimens, may be PAS positive, even if duodenal biopsy specimens are negative (<link linkend="ch0087s000000li0003">3</link>).</para>
        <para id="ch0087s000000p0024">Experienced pathologists are often able to assess the success of treatment, because PAS-positive particulate structures (untreated patient) shift to faintly PAS-positive cytoplasm without granulation (successfully treated patient) (<link linkend="ch0087s000000li0066">66</link>).</para>
        <anchor id="ch0087s000000a0039"/>
        <beginpage pagenum="1326"/>
      </sect2>
      <sect2 id="ch0087s0009s0002">
        <title>Transmission Electron Microscopy</title>
        <anchor id="ch0087s000009a0003"/>
        <anchor id="ch0087s000000a0040"/>
        <para id="ch0087s000000p0025">Transmission electron microscopy (EM) is suitable to identify<emphasis>T. whipplei</emphasis> in ultrathin histological sections from infected organs due to its unique trilamellar cell wall (<link linkend="ch0087s000000li0010">10</link>). As transmission EM is laborious, time-consuming, and not routinely available in clinical laboratories, its use is restricted to the analysis of special cases (<link linkend="ch0087s000000li0065">65</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0087s0010">
      <title>Antigen Detection: IHC</title>
      <anchor id="ch0087s000010a0001"/>
      <anchor id="ch0087s000000a0041"/>
      <para id="ch0087s000000p0026">IHC with polyclonal rabbit anti-<emphasis>T. whipplei</emphasis> antibodies is able to specifically visualize bacteria in histological sections from various tissues and in circulating monocytes (<link linkend="ch0087s000000li0067">67</link>, <link linkend="ch0087s000000li0068">68</link>). Compared to PAS staining, IHC is more specific and sensitive in untreated Whipple disease but less sensitive after treatment (<link linkend="ch0087s000000li0067">67</link>). However, as antiserum is not commercially available, this method is restricted to a few specialized laboratories. Like FISH, IHC may be used to confirm positive results obtained by PAS staining.</para>
    </sect1>
    <sect1 id="ch0087s0011">
      <title>Nucleic Acid Detection</title>
      <anchor id="ch0087s000011a0001"/>
      <anchor id="ch0087s000000a0042"/>
      <sect2 id="ch0087s0011s0001">
        <title>FISH</title>
        <anchor id="ch0087s000011a0002"/>
        <anchor id="ch0087s000000a0043"/>
        <para id="ch0087s000000p0027">FISH is a molecular technique using fluorescently labeled oligonucleotide probes to target<emphasis>T. whipplei</emphasis> 16S rRNA in histological sections. FISH is particularly useful to verify and localize <emphasis>T. whipplei</emphasis> in extraintestinal tissues (<link linkend="ch0087s000000li0052">52</link>, <link linkend="ch0087s000000li0054">54</link>, <link linkend="ch0087s000000li0069">69</link>, <link linkend="ch0087s000000li0070">70</link>) or to confirm PAS-positive staining of small bowel biopsy specimens (<anchor id="ch0087s000000a0044"/><link linkend="ch0087s000000a0013">Fig. 2</link> and 3). FISH probes target the ribosomes, which correlate with the activity of bacteria, whereas PAS staining stays positive for prolonged periods during therapy. However, detection of <emphasis>T. whipplei</emphasis> by FISH is available only in specialized centers.</para>
      </sect2>
      <sect2 id="ch0087s0011s0002">
        <title>NAAT</title>
        <anchor id="ch0087s000011a0003"/>
        <anchor id="ch0087s000000a0045"/>
        <para id="ch0087s000000p0028">Although PAS staining used to be the first-line method for analysis of duodenal biopsy specimens, NAAT outcompetes PAS staining with respect to performance, including sensitivity, specificity, time to result, and hands-on time (<link linkend="ch0087s000000li0065">65</link>). FDA-cleared tests are currently not available, but reference and public health laboratories generally use in-house PCR protocols (<link linkend="ch0087s000000li0071">71</link>, <link linkend="ch0087s000000li0072">72</link>) and are therefore responsible for validation and quality control procedures (<link linkend="ch0087s000000li0063">63</link>) to exclude false-negative and false-positive results (e.g., as a consequence of DNA contamination). High-quality assays use real-time PCR protocols with hybridization probes (<link linkend="ch0087s000000li0028">28</link>, <link linkend="ch0087s000000li0073">73</link>). Assays should be designed so as not to cross-react with normal microbiota that might be copresent (e.g., in saliva or stool specimens). PCR results should always be interpreted in the context of clinical and histopathological findings. If PCR findings are questionable, they should be confirmed with a second specimen, by amplification of a second target sequence or by staining (<link linkend="ch0087s000000li0001">1</link>, <link linkend="ch0087s000000li0002">2</link>, <link linkend="ch0087s000000li0059">59</link>).</para>
        <para id="ch0087s000000p0029"><emphasis>T. whipplei</emphasis>-specific NAAT can be performed with tissue specimens or fluid from any infected organ (e.g., duodenal biopsy tissue, lymph nodes, heart valves, vitreous fluid, synovial fluid, urine, and CSF). Analysis of peripheral blood samples using NAAT is possible, but negative results do not rule out infection (<link linkend="ch0087s000000li0074">74</link>). Universal bacterial (“eubacterial” or “panbacterial”) PCR (16S rRNA gene amplification) followed by Sanger sequence analysis shows lower sensitivity than <emphasis>T. whipplei</emphasis>-specific PCR protocols, although the use of next-generation sequencing may improve sensitivity (<link linkend="ch0087s000000li0075">75</link>, <link linkend="ch0087s000000li0076">76</link>). Therefore, the former approach is best suited to examination of specimens containing high bacterial loads, such as resected heart valves in cases of <emphasis>T. whipplei</emphasis> endocarditis (<link linkend="ch0087s000000li0051">51</link>, <link linkend="ch0087s000000li0052">52</link>), and may fail to detect smaller amounts of bacteria, such as those present in CSF.</para>
      </sect2>
      <sect2 id="ch0087s0011s0003">
        <title>ISOLATION PROCEDURES, IDENTIFICATION, AND TYPING SYSTEMS</title>
        <anchor id="ch0087s000011a0004"/>
        <anchor id="ch0087s000000a0046"/>
        <para id="ch0087s000000p0030">Isolation of<emphasis>T. whipplei</emphasis> from clinical samples using long-term culture methods (<link linkend="ch0087s000000li0009">9</link>, <link linkend="ch0087s000000li0012">12</link>, <link linkend="ch0087s000000li0018">18</link>) is challenging and established in only a very few laboratories worldwide.</para>
        <para id="ch0087s000000p0031">Identification of<emphasis>T. whipplei</emphasis> and typing methods for epidemiological research are exclusively based on analyses of PCR-amplified DNA sequences and can be performed directly from sample material without cultivation. The limited resolution of classically used targets like the 16S-23S rRNA intergenic spacer region or domain III of 23S rRNA has been improved by the analysis of four highly variable genomic sequences, revealing more than 140 sequence types from Europe, Africa, Asia, and North America (reference <link linkend="ch0087s000000li0001">1</link> and references therein; <link linkend="ch0087s000000li0077">77</link>, <link linkend="ch0087s000000li0078">78</link>). No correlation between <emphasis>T. whipplei</emphasis> sequence types and pathogenicity, virulence, or specific organotropism has been described to date.</para>
      </sect2>
      <sect2 id="ch0087s0011s0004">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0087s000011a0005"/>
        <anchor id="ch0087s000000a0047"/>
        <para id="ch0087s000000p0032">Although several attempts have been made to identify<emphasis>T. whipplei</emphasis> proteins as antigens for serodiagnosis of Whipple disease (<link linkend="ch0087s000000li0079">79</link>–<link linkend="ch0087s000000li0081">81</link>), no routine diagnostic assay with sufficient sensitivity and specificity is currently available. Indirect immunofluorescence assays using <emphasis>T. whipplei</emphasis> cell cultures as antigens have proven to be problematic, because control groups show a high prevalence of reactive immunoglobulin G and a large proportion of patients with Whipple disease are negative for <emphasis>T. whipplei</emphasis>-reactive IgM (<link linkend="ch0087s000000li0009">9</link>, <link linkend="ch0087s000000li0081">81</link>).</para>
      </sect2>
      <sect2 id="ch0087s0011s0005">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0087s000011a0006"/>
        <anchor id="ch0087s000000a0048"/>
        <para id="ch0087s000000p0033">In<emphasis>in vitro</emphasis> tests, <emphasis>T. whipplei</emphasis> is susceptible to many antibiotics, including penicillin G, macrolides, doxycycline, rifampin, chloramphenicol, and trimethoprim-sulfamethoxazole (<link linkend="ch0087s000000li0082">82</link>). Ciprofloxacin is inactive (<link linkend="ch0087s000000li0083">83</link>). Ceftriaxone and gentamicin show high-level activity against extracellular but not intracellular bacteria. Susceptibility to imipenem is variable. <emphasis>T. whipplei</emphasis> is resistant to trimethoprim, as the gene encoding its target (dihydrofolate reductase) is absent from its genome (<link linkend="ch0087s000000li0084">84</link>). Consequently, sulfamethoxazole is the active compound of trimethoprim-sulfamethoxazole; however, reduced susceptibility and resistance of clinical <emphasis>T. whipplei</emphasis> isolates to sulfonamides have also been reported (reference <link linkend="ch0087s000000li0085">85</link> and references therein).</para>
        <para id="ch0087s000000p0034">If left untreated, systemic Whipple disease can be fatal. The optimal regimen for treatment of systemic or isolated infection is incompletely defined. The current first-line recommendation consists of initial therapy with ceftriaxone (2 g intravenously [i.v.] once every 24 h) for 2 to 4 weeks to achieve clearance of<emphasis>T. whipplei</emphasis> from the CNS, followed by 1 year of oral treatment with trimethoprim-sulfamethoxazole (160/800 mg orally [p.o.] twice every 24 h) (<link linkend="ch0087s000000li0037">37</link>, <link linkend="ch0087s000000li0086">86</link>, <link linkend="ch0087s000000li0087">87</link>). Subsequent lifelong prophylactic doxycycline to prevent reactivation or reinfection has been proposed by Biagi et al. (<link linkend="ch0087s000000li0088">88</link>). Substantial clinical improvement within 7 to 21 days and complete recovery can be achieved in most patients. However, trimethoprim-sulfamethoxazole treatment failures and relapses have been documented (reference <link linkend="ch0087s000000li0089">89</link> and references therein). An alternative regimen showing bactericidal activity consists of a combination of hydroxychloroquine (200 mg p.o. three times every 24 h) and doxycycline (100 mg p.o. twice every 24 h) for 1 year, followed by lifelong monotherapy with doxycycline (<link linkend="ch0087s000000li0089">89</link>). Hydroxychloroquine is thought to neutralize the low pH in acidic vacuoles in which <emphasis>T. whipplei</emphasis> replicates (<link linkend="ch0087s000000li0030">30</link>, <link linkend="ch0087s000000li0031">31</link>). However, relapse of Whipple disease following therapy with doxycycline plus hydroxychloroquine has been reported (<link linkend="ch0087s000000li0090">90</link>).</para>
        <anchor id="ch0087s000000a0049"/>
        <beginpage pagenum="1327"/>
        <para id="ch0087s000000p0035">In the case of cerebral involvement, patients may benefit from adjunctive corticosteroid therapy. Corticosteroids have also been suggested for use in patients with IRIS (<link linkend="ch0087s000000li0091">91</link>). Immune therapy with gamma interferon was successful in a patient with relapsing disease (<link linkend="ch0087s000000li0092">92</link>).</para>
      </sect2>
      <sect2 id="ch0087s0011s0006">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0087s000011a0007"/>
        <anchor id="ch0087s000000a0050"/>
        <para id="ch0087s000000p0036">Following an initial diagnosis of Whipple disease, test results and their correlation with the clinical presentation of the patient should be reviewed and a decision regarding the need for confirmatory diagnostic approaches with a second, independent sample or method should be made. If NAAT leads to an initial diagnosis of Whipple disease, a positive NAAT might be corroborated by either sequence analysis or a NAAT targeting another<emphasis>T. whipplei</emphasis>-specific DNA sequence; examination of small bowel biopsy specimens, CSF, and, where appropriate, urine might be considered. For NAAT, fresh tissue specimens are preferable to those that are formalin fixed and paraffin embedded, because the sensitivity is higher and even elaborate methods of DNA extraction from paraffin blocks still show a higher risk of DNA contamination. Negative blood sample NAAT results do not rule out infection, due to low sensitivity with this specimen type. Positive NAAT results, in the case of saliva and stool, do not differentiate carrier states from clinical disease; however, in the case of urine, a positive finding may tentatively indicate infection.</para>
        <para id="ch0087s000000p0037">Once the laboratory detection of<emphasis>T. whipplei</emphasis> is confirmed, a decision on the treatment regimen and follow-up strategy must be made. In the case of any doubt about the diagnosis, therapy, and/or follow-up for a patient, or when complications occur (e.g., primary treatment failure or relapse), experts from reference centers or specialized laboratories should be contacted.</para>
      </sect2>
      <sect2 id="ch0087s0011s0007">
        <title>REFERENCES</title>
        <anchor id="ch0087s000011a0008"/>
        <anchor id="ch0087s000000a0051"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0087s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Dolmans RA, Boel CH, Lacle MM, Kusters JG.</emphasis> 2017. Clinical manifestations, treatment, and diagnosis of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> infections. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>529–555.</para>
          </listitem>
          <listitem id="ch0087s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Marth T, Moos V, Müller C, Biagi F, Schneider T.</emphasis> 2016. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> infection and Whipple’s disease. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>e13–e22.</para>
          </listitem>
          <listitem id="ch0087s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Moos V, Schneider T.</emphasis> 2011. Changing paradigms in Whipple’s disease and infection with <citetitle><emphasis>Tropheryma whipplei. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>1151–1158.</para>
          </listitem>
          <listitem id="ch0087s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Wilson KH, Blitchington R, Frothingham R, Wilson JA.</emphasis> 1991. Phylogeny of the Whipple’s-disease-associated bacterium. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">338</emphasis><emphasis role="strong">:</emphasis>474–475.</para>
          </listitem>
          <listitem id="ch0087s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D.</emphasis> 2001. Description of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> gen. nov., sp. nov., the Whipple’s disease bacillus. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1471–1479.</para>
          </listitem>
          <listitem id="ch0087s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Sen A, Daubin V, Abrouk D, Gifford I, Berry AM, Normand P.</emphasis> 2014. Phylogeny of the class <citetitle><emphasis>Actinobacteria</emphasis></citetitle> revisited in the light of complete genomes. The orders ‘Frankiales’ and <citetitle><emphasis>Micrococcales</emphasis></citetitle> should be split into coherent entities: proposal of <citetitle><emphasis>Frankiales</emphasis></citetitle> ord. nov., <citetitle><emphasis>Geodermatophilales</emphasis></citetitle> ord. nov., <citetitle><emphasis>Acidothermales</emphasis></citetitle> ord. nov. and <citetitle><emphasis>Nakamurellales</emphasis></citetitle> ord. nov. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>3821–3832.</para>
          </listitem>
          <listitem id="ch0087s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, von Herbay A, Goble A, Rutter S, Squares R, Squares S, Barrell BG, Parkhill J, Relman DA.</emphasis> 2003. Sequencing and analysis of the genome of the Whipple’s disease bacterium <citetitle><emphasis>Tropheryma whipplei. Lancet</emphasis></citetitle> <emphasis role="strong">361</emphasis><emphasis role="strong">:</emphasis>637–644.</para>
          </listitem>
          <listitem id="ch0087s000000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Vankeerberghen A, Jonckheere S, De Raeve H, Caluwe R, De Beenhouwer H.</emphasis> 2018. Novel <citetitle><emphasis>Tropheryma</emphasis></citetitle> species in a lung biopsy sample from a kidney transplant recipient. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">24:</emphasis>548.E5–548.E8.</para>
          </listitem>
          <listitem id="ch0087s000000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital-Durand D, Marrie TJ.</emphasis> 2000. Cultivation of the bacillus of Whipple’s disease. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">342</emphasis><emphasis role="strong">:</emphasis>620–625.</para>
          </listitem>
          <listitem id="ch0087s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Silva MT, Macedo PM, Moura Nunes JF.</emphasis> 1985. Ultrastructure of bacilli and the bacillary origin of the macrophagic inclusions in Whipple’s disease. <citetitle><emphasis>J Gen Microbiol</emphasis></citetitle> <emphasis role="strong">131:</emphasis>1001–1013.</para>
          </listitem>
          <listitem id="ch0087s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Schoedon G, Goldenberger D, Forrer R, Gunz A, Dutly F, Höchli M, Altwegg M, Schaffner A.</emphasis> 1997. Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">176</emphasis><emphasis role="strong">:</emphasis>672–677.</para>
          </listitem>
          <listitem id="ch0087s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Fenollar F, Birg ML, Gauduchon V, Raoult D.</emphasis> 2003. Culture of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> from human samples: a 3-year experience (1999 to 2002). <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>3816–3822.</para>
          </listitem>
          <listitem id="ch0087s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Puéchal X, Fenollar F, Raoult D.</emphasis> 2007. Cultivation of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> from the synovial fluid in Whipple’s arthritis. <citetitle><emphasis>Arthritis Rheum</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1713–1718.</para>
          </listitem>
          <listitem id="ch0087s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Drancourt M, Raoult D, Lépidi H, Fénollar F, Birg ML, Bodaghi B, Hoang PL, Lelièvre JD.</emphasis> 2003. Culture of <citetitle><emphasis>Tropheryma whippelii</emphasis></citetitle> from the vitreous fluid of a patient presenting with unilateral uveitis. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">139:</emphasis>1046–1047.</para>
          </listitem>
          <listitem id="ch0087s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Angelakis E, Fenollar F, Lepidi H, Birg ML, Raoult D.</emphasis> 2010. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in the skin of patients with classic Whipple’s disease. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">61</emphasis><emphasis role="strong">:</emphasis>266–269.</para>
          </listitem>
          <listitem id="ch0087s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">La Scola B, Fenollar F, Perreal C, Raoult D.</emphasis> 2011. Epidemiologic implications of the first isolation and cultivation of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> from a saliva sample. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">154</emphasis><emphasis role="strong">:</emphasis>443–444.</para>
          </listitem>
          <listitem id="ch0087s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Raoult D, Fenollar F, Birg ML.</emphasis> 2006. Culture of <citetitle><emphasis>T. whipplei</emphasis></citetitle> from the stool of a patient with Whipple’s disease. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">355:</emphasis>1503–1505.</para>
          </listitem>
          <listitem id="ch0087s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D.</emphasis> 2003. Genome-based design of a cell-free culture medium for <citetitle><emphasis>Tropheryma whipplei. Lancet</emphasis></citetitle> <emphasis role="strong">362</emphasis><emphasis role="strong">:</emphasis>447–449.</para>
          </listitem>
          <listitem id="ch0087s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Lagier JC, Lepidi H, Raoult D, Fenollar F.</emphasis> 2010. Systemic <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">89</emphasis><emphasis role="strong">:</emphasis>337–345.</para>
          </listitem>
          <listitem id="ch0087s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Keita AK, Dubot-Pérès A, Phommasone K, Sibounheuang B, Vongsouvath M, Mayxay M, Raoult D, Newton PN, Fenollar F.</emphasis> 2015. High prevalence of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in Lao kindergarten children. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e0003538.</para>
          </listitem>
          <listitem id="ch0087s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Keita AK, Mediannikov O, Ratmanov P, Diatta G, Bassene H, Roucher C, Tall A, Sokhna C, Trape JF, Raoult D, Fenollar F.</emphasis> 2013. Looking for <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> source and reservoir in rural Senegal. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">88</emphasis><emphasis role="strong">:</emphasis>339–343.</para>
          </listitem>
          <listitem id="ch0087s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Maiwald M, Schuhmacher F, Ditton HJ, von Herbay A.</emphasis> 1998. Environmental occurrence of the Whipple’s disease bacterium (<citetitle><emphasis>Tropheryma whippelii</emphasis></citetitle>). <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">64</emphasis><emphasis role="strong">:</emphasis>760–762.</para>
          </listitem>
          <listitem id="ch0087s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Schöniger-Hekele M, Petermann D, Weber B, Müller C.</emphasis> 2007. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in the environment: survey of sewage plant influxes and sewage plant workers. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">73:</emphasis>2033–2035.</para>
          </listitem>
          <listitem id="ch0087s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Fenollar F, Keita AK, Buffet S, Raoult D.</emphasis> 2012. Intrafamilial circulation of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>, France. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18</emphasis><emphasis role="strong">:</emphasis>949–955.</para>
          </listitem>
          <listitem id="ch0087s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Keita AK, Raoult D, Fenollar F.</emphasis> 2013. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> as a commensal bacterium. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>57–71.</para>
          </listitem>
          <listitem id="ch0087s000000li0026" role="bibliographyEntry">
            <anchor id="ch0087s000000a0052"/>
            <para>26.<emphasis role="strong">Fenollar F, Marth T, Lagier JC, Angelakis E, Raoult D.</emphasis> 2015. Sewage workers with low antibody responses may be colonized successively by several <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> strains. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">35:</emphasis>51–55.</para>
          </listitem>
          <listitem id="ch0087s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D.</emphasis> 2008. Value of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>659–667.</para>
          </listitem>
          <listitem id="ch0087s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Fenollar F, Trani M, Davoust B, Salle B, Birg ML, Rolain JM, Raoult D.</emphasis> 2008. Prevalence of asymptomatic <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> carriage among humans and nonhuman primates. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">197</emphasis><emphasis role="strong">:</emphasis>880–887.</para>
          </listitem>
          <listitem id="ch0087s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Moos V, Schneider T.</emphasis> 2012. The role of T cells in the pathogenesis of classical Whipple’s disease. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>253–255.</para>
          </listitem>
          <listitem id="ch0087s000000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Ghigo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, Mege JL.</emphasis> 2002. Survival of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>, the agent of Whipple’s disease, requires phagosome acidification. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">70:</emphasis>1501–1506.</para>
          </listitem>
          <listitem id="ch0087s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Mottola G, Boucherit N, Trouplin V, Oury Barry A, Soubeyran P, Mege JL, Ghigo E.</emphasis> 2014. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>, the agent of Whipple’s disease, affects the early to late phagosome transition and survives in a Rab5- and Rab7-positive compartment. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e89367.</para>
          </listitem>
          <listitem id="ch0087s000000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Schinnerling K, Geelhaar-Karsch A, Allers K, Friebel J, Conrad K, Loddenkemper C, Kühl AA, Erben U, Ignatius R, Moos V, Schneider T.</emphasis> 2015. Role of dendritic cells in the pathogenesis of Whipple’s disease. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">83</emphasis><emphasis role="strong">:</emphasis>482–491.</para>
          </listitem>
          <listitem id="ch0087s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Geelhaar A, Moos V, Schinnerling K, Allers K, Loddenkemper C, Fenollar F, LaScola B, Raoult D, Schneider T.</emphasis> 2010. Specific and nonspecific B-cell function in the small intestines of patients with Whipple’s disease. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">78:</emphasis>4589–4592.</para>
          </listitem>
          <listitem id="ch0087s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Martinetti M, Biagi F, Badulli C, Feurle GE, Müller C, Moos V, Schneider T, Marth T, Marchese A, Trotta L, Sachetto S, Pasi A, De Silvestri A, Salvaneschi L, Corazza GR.</emphasis> 2009. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple’s disease. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">136:</emphasis>2289–2294.</para>
          </listitem>
          <listitem id="ch0087s000000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Guérin A, Kerner G, Marr N, Markle JG, Fenollar F, Wong N, Boughorbel S, Avery DT, Ma CS, Bougarn S, Bouaziz M, Béziat V, Della Mina E, Oleaga-Quintas C, Lazarov T, Worley L, Nguyen T, Patin E, Deswarte C, Martinez-Barricarte R, Boucherit S, Ayral X, Edouard S, Boisson-Dupuis S, Rattina V, Bigio B, Vogt G, Geissmann F, Quintana-Murci L, Chaussabel D, Tangye SG, Raoult D, Abel L, Bustamante J, Casanova JL.</emphasis> 2018. IRF4 haploinsufficiency in a family with Whipple’s disease. <citetitle><emphasis>eLife</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e32340.</para>
          </listitem>
          <listitem id="ch0087s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Schnider PJ, Reisinger EC, Berger T, Krejs GJ, Auff E.</emphasis> 1997. Treatment guidelines in central nervous system Whipple’s disease. <citetitle><emphasis>Ann Neurol</emphasis></citetitle> <emphasis role="strong">41</emphasis><emphasis role="strong">:</emphasis>561–562.</para>
          </listitem>
          <listitem id="ch0087s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Apstein MD, Schneider T.</emphasis> Whipple’s disease. <citetitle><emphasis>In</emphasis></citetitle> Calderwood SB (ed), <citetitle><emphasis>UpToDate.</emphasis></citetitle> UpToDate Inc, Waltham, MA. <ulink url="http://www.uptodate.com">http://www.uptodate.com</ulink>. Accessed 24 January 2018.</para>
          </listitem>
          <listitem id="ch0087s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Günther U, Moos V, Offenmüller G, Oelkers G, Heise W, Moter A, Loddenkemper C, Schneider T.</emphasis> 2015. Gastrointestinal diagnosis of classical Whipple disease: clinical, endoscopic, and histopathologic features in 191 patients. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">94:</emphasis>e714.</para>
          </listitem>
          <listitem id="ch0087s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M.</emphasis> 1997. Whipple’s disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">113</emphasis><emphasis role="strong">:</emphasis>434–441.</para>
          </listitem>
          <listitem id="ch0087s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Puéchal X.</emphasis> 2016. Whipple’s arthritis. <citetitle><emphasis>Joint Bone Spine</emphasis></citetitle> <emphasis role="strong">83</emphasis><emphasis role="strong">:</emphasis>631–635.</para>
          </listitem>
          <listitem id="ch0087s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Boumaza A, Mezouar S, Bardou M, Raoult D, Mège JL, Desnues B.</emphasis> 2021. Tumor necrosis factor inhibitors exacerbate Whipple’s disease by reprogramming macrophage and inducing apoptosis. <citetitle><emphasis>Front Immunol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>667357.</para>
          </listitem>
          <listitem id="ch0087s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Marth T.</emphasis> 2015. Systematic review: whipple’s disease (<citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> infection) and its unmasking by tumour necrosis factor inhibitors. <citetitle><emphasis>Aliment Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">41</emphasis><emphasis role="strong">:</emphasis>709–724.</para>
          </listitem>
          <listitem id="ch0087s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Meunier M, Puechal X, Hoppé E, Soubrier M, Dieudé P, Berthelot JM, Caramaschi P, Gottenberg JE, Gossec L, Morel J, Maury E, Wipff J, Kahan A, Allanore Y.</emphasis> 2013. Rheumatic and musculoskeletal features of Whipple disease: a report of 29 cases. <citetitle><emphasis>J Rheumatol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2061–2066.</para>
          </listitem>
          <listitem id="ch0087s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Glaser C, Rieg S, Wiech T, Scholz C, Endres D, Stich O, Hasselblatt P, Geißdörfer W, Bogdan C, Serr A, Häcker G, Voll RE, Thiel J, Venhoff N.</emphasis> 2017. Whipple’s disease mimicking rheumatoid arthritis can cause misdiagnosis and treatment failure. <citetitle><emphasis>Orphanet J Rare Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>99.</para>
          </listitem>
          <listitem id="ch0087s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Lehmann P, Ehrenstein B, Hartung W, Dragonas C, Reischl U, Fleck M.</emphasis> 2017. PCR analysis is superior to histology for diagnosis of Whipple’s disease mimicking seronegative rheumatic diseases. <citetitle><emphasis>Scand J Rheumatol</emphasis></citetitle> <emphasis role="strong">46</emphasis><emphasis role="strong">:</emphasis>138–142.</para>
          </listitem>
          <listitem id="ch0087s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Compain C, Sacre K, Puéchal X, Klein I, Vital-Durand D, Houeto JL, De Broucker T, Raoult D, Papo T.</emphasis> 2013. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">92</emphasis><emphasis role="strong">:</emphasis>324–330.</para>
          </listitem>
          <listitem id="ch0087s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Lagier JC, Raoult D.</emphasis> 2018. Whipple’s disease and <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> infections: when to suspect them and how to diagnose and treat them. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">31</emphasis><emphasis role="strong">:</emphasis>463–470.</para>
          </listitem>
          <listitem id="ch0087s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Dobbins WO.</emphasis> 1987. <citetitle><emphasis>Whipple’s Disease.</emphasis></citetitle> Charles C Thomas, Springfield, IL.</para>
          </listitem>
          <listitem id="ch0087s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Schoenberger SD, Thinda S, Kim SJ.</emphasis> 2012. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> crystalline keratopathy: report of a case and updated review of the literature. <citetitle><emphasis>Case Rep Ophthalmol Med</emphasis></citetitle> <emphasis role="strong">2012:</emphasis>707898.</para>
          </listitem>
          <listitem id="ch0087s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Touitou V, Fenollar F, Cassoux N, Merle-Beral H, LeHoang P, Amoura Z, Drancourt M, Bodaghi B.</emphasis> 2012. Ocular Whipple’s disease: therapeutic strategy and long-term follow-up. <citetitle><emphasis>Ophthalmology</emphasis></citetitle> <emphasis role="strong">119:</emphasis>1465–1469.</para>
          </listitem>
          <listitem id="ch0087s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Fenollar F, Célard M, Lagier JC, Lepidi H, Fournier PE, Raoult D.</emphasis> 2013. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> endocarditis. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>1721–1730.</para>
          </listitem>
          <listitem id="ch0087s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Geissdörfer W, Moos V, Moter A, Loddenkemper C, Jansen A, Tandler R, Morguet AJ, Fenollar F, Raoult D, Bogdan C, Schneider T.</emphasis> 2012. High frequency of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in culture-negative endocarditis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50</emphasis><emphasis role="strong">:</emphasis>216–222.</para>
          </listitem>
          <listitem id="ch0087s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Liesman RM, Pritt BS, Maleszewski JJ, Patel R.</emphasis> 2017. Laboratory diagnosis of infective endocarditis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2599–2608.</para>
          </listitem>
          <listitem id="ch0087s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Moter A, Janneck M, Wolters M, Iking-Konert C, Wiessner A, Loddenkemper C, Hartleben B, Lütgehetmann M, Schmidt J, Langbehn U, Janssen S, Geelhaar-Karsch A, Schneider T, Moos V, Rohde H, Kikhney J, Wiech T.</emphasis> 2019. Potential role for urine polymerase chain reaction in the diagnosis of Whipple’s disease. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">68:</emphasis>1089–1097.</para>
          </listitem>
          <listitem id="ch0087s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Schaller J, Carlson JA.</emphasis> 2009. Erythema nodosum-like lesions in treated Whipple’s disease: signs of immune reconstitution inflammatory syndrome. <citetitle><emphasis>J Am Acad Dermatol</emphasis></citetitle> <emphasis role="strong">60</emphasis><emphasis role="strong">:</emphasis>277–288.</para>
          </listitem>
          <listitem id="ch0087s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Moos V, Feurle GE, Schinnerling K, Geelhaar A, Friebel J, Allers K, Moter A, Kikhney J, Loddenkemper C, Kühl AA, Erben U, Fenollar F, Raoult D, Schneider T.</emphasis> 2013. Immunopathology of immune reconstitution inflammatory syndrome in Whipple’s disease. <citetitle><emphasis>J Immunol</emphasis></citetitle> <emphasis role="strong">190:</emphasis>2354–2361.</para>
          </listitem>
          <listitem id="ch0087s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Raoult D, Fenollar F, Rolain JM, Minodier P, Bosdure E, Li W, Garnier JM, Richet H.</emphasis> 2010. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in children with gastroenteritis. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>776–782.</para>
          </listitem>
          <listitem id="ch0087s000000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Fenollar F, Minodier P, Boutin A, Laporte R, Brémond V, Noël G, Miramont S, Richet H, Benkouiten S, Lagier JC, Gaudart J, Jouve JL, Raoult D.</emphasis> 2016. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> associated with diarrhoea in young children. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22</emphasis><emphasis role="strong">:</emphasis>869–874.</para>
          </listitem>
          <listitem id="ch0087s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Edouard S, Fenollar F, Raoult D.</emphasis> 2012. The rise of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>: a 12-year retrospective study of PCR diagnoses in our reference center. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3917–3920.</para>
          </listitem>
          <listitem id="ch0087s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Lagier JC, Papazian L, Fenollar F, Edouard S, Melenotte C, Laroumagne S, Michel G, Martin C, Gainnier M, Lions C, Carrieri P, Stein A, Brouqui P, Raoult D.</emphasis> 2016. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> DNA in bronchoalveolar lavage samples: a case control study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22</emphasis><emphasis role="strong">:</emphasis>875–879.</para>
          </listitem>
          <listitem id="ch0087s000000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Moter A, Kikhney J, Moos V, Wiech T, Rohde H, Wolters M.</emphasis> 2019. Reply to Tison and Saraux. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">69:</emphasis>905.</para>
          </listitem>
          <listitem id="ch0087s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Raoult D.</emphasis> 2019. From Whipple disease to <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> infection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">68:</emphasis>1098–1099.</para>
          </listitem>
          <listitem id="ch0087s000000li0063" role="bibliographyEntry">
            <anchor id="ch0087s000000a0053"/>
            <para>63.<emphasis role="strong">Rolain JM, Fenollar F, Raoult D.</emphasis> 2007. False positive PCR detection of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in the saliva of healthy people. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>48.</para>
          </listitem>
          <listitem id="ch0087s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Keita AK, Brouqui P, Badiaga S, Benkouiten S, Ratmanov P, Raoult D, Fenollar F.</emphasis> 2013. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> prevalence strongly suggests human transmission in homeless shelters. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>e67–e68.</para>
          </listitem>
          <listitem id="ch0087s000000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Müller SA, Vogt P, Altwegg M, Seebach JD.</emphasis> 2005. Deadly carousel or difficult interpretation of new diagnostic tools for Whipple’s disease: case report and review of the literature. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">33:</emphasis>39–42.</para>
          </listitem>
          <listitem id="ch0087s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">von Herbay A.</emphasis> 2001. [Whipple’s disease. Histologic diagnosis after the discovery of <citetitle><emphasis>Tropheryma whippelii.</emphasis></citetitle>]. <citetitle><emphasis>Pathologe</emphasis></citetitle> <emphasis role="strong">22:</emphasis>82–88.</para>
          </listitem>
          <listitem id="ch0087s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, Chappuis M, Sahel J, Raoult D.</emphasis> 2003. Whipple’s disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. <citetitle><emphasis>Hum Pathol</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>589–596.</para>
          </listitem>
          <listitem id="ch0087s000000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Raoult D, Lepidi H, Harle JR.</emphasis> 2001. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> circulating in blood monocytes. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">345:</emphasis>548.</para>
          </listitem>
          <listitem id="ch0087s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Fredricks DN, Relman DA.</emphasis> 2001. Localization of <citetitle><emphasis>Tropheryma whippelii</emphasis></citetitle> rRNA in tissues from patients with Whipple’s disease. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">183:</emphasis>1229–1237.</para>
          </listitem>
          <listitem id="ch0087s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Mallmann C, Siemoneit S, Schmiedel D, Petrich A, Gescher DM, Halle E, Musci M, Hetzer R, Göbel UB, Moter A.</emphasis> 2010. Fluorescence <citetitle><emphasis>in situ</emphasis></citetitle> hybridization to improve the diagnosis of endocarditis: a pilot study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>767–773.</para>
          </listitem>
          <listitem id="ch0087s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Hinrikson HP, Dutly F, Altwegg M.</emphasis> 2000. Evaluation of a specific nested PCR targeting domain III of the 23S rRNA gene of “<citetitle><emphasis>Tropheryma whippelii</emphasis></citetitle>” and proposal of a classification system for its molecular variants. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38</emphasis><emphasis role="strong">:</emphasis>595–599.</para>
          </listitem>
          <listitem id="ch0087s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Relman DA, Schmidt TM, MacDermott RP, Falkow S.</emphasis> 1992. Identification of the uncultured bacillus of Whipple’s disease. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">327</emphasis><emphasis role="strong">:</emphasis>293–301.</para>
          </listitem>
          <listitem id="ch0087s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Moter A, Schmiedel D, Petrich A, Wiessner A, Kikhney J, Schneider T, Moos V, Göbel UB, Reischl U.</emphasis> 2013. Validation of an <citetitle><emphasis>rpoB</emphasis></citetitle> gene PCR assay for detection of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>: 10 years’ experience in a national reference laboratory. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3858–3861.</para>
          </listitem>
          <listitem id="ch0087s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Marth T, Fredericks D, Strober W, Relman DA.</emphasis> 1996. Limited role for PCR-based diagnosis of Whipple’s disease from peripheral blood mononuclear cells. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">348:</emphasis>66–67.</para>
          </listitem>
          <listitem id="ch0087s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, Sodergren E, Mitreva M, Abubucker S, Martin J, Yao G, Campbell TB, Flores SC, Ackerman G, Stombaugh J, Ursell L, Beck JM, Curtis JL, Young VB, Lynch SV, Huang L, Weinstock GM, Knox KS, Twigg H, Morris A, Ghedin E, Bushman FD, Collman RG, Knight R, Fontenot AP, Lung HIV Microbiome Project.</emphasis> 2013. Widespread colonization of the lung by <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in HIV infection. <citetitle><emphasis>Am J Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">187:</emphasis>1110–1117.</para>
          </listitem>
          <listitem id="ch0087s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Sze MA, Xu S, Leung JM, Vucic EA, Shaipanich T, Moghadam A, Harris M, Guillemi S, Sinha S, Nislow C, Murphy D, Hague C, Leipsic J, Lam S, Lam W, Montaner JS, Sin DD, Man SF.</emphasis> 2016. The bronchial epithelial cell bacterial microbiome and host response in patients infected with human immunodeficiency virus. <citetitle><emphasis>BMC Pulm Med</emphasis></citetitle> <emphasis role="strong">16:</emphasis>142.</para>
          </listitem>
          <listitem id="ch0087s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Müller C, Moos V, Marth T, Altwegg M, Calligaris-Maibach RC, Schneider T, Biagi F, La Scola B, Raoult D.</emphasis> 2008. Genotyping reveals a wide heterogeneity of <citetitle><emphasis>Tropheryma whipplei. Microbiol (Reading)</emphasis></citetitle> <emphasis role="strong">154</emphasis><emphasis role="strong">:</emphasis>521–527.</para>
          </listitem>
          <listitem id="ch0087s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Rollin DC, Paddock CD, Pritt BS, Cunningham SA, Denison AM.</emphasis> 2017. Genotypic analysis of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> from patients with Whipple disease in the Americas. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">70</emphasis><emphasis role="strong">:</emphasis>891–895.</para>
          </listitem>
          <listitem id="ch0087s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Kowalczewska M, Villard C, Lafitte D, Fenollar F, Raoult D.</emphasis> 2009. Global proteomic pattern of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle>: a Whipple’s disease bacterium. <citetitle><emphasis>Proteomics</emphasis></citetitle> <emphasis role="strong">9:</emphasis>1593–1616.</para>
          </listitem>
          <listitem id="ch0087s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Liang Z, La Scola B, Raoult D.</emphasis> 2002. Monoclonal antibodies to immunodominant epitope of <citetitle><emphasis>Tropheryma whipplei. Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>156–159.</para>
          </listitem>
          <listitem id="ch0087s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Morgenegg S, Maibach R, Chaperon DN, Herzog K, Altwegg M.</emphasis> 2001. Antibodies against recombinant heat shock protein 65 of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in patients with and without Whipple’s disease. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>299–306.</para>
          </listitem>
          <listitem id="ch0087s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Boulos A, Rolain JM, Mallet MN, Raoult D.</emphasis> 2005. Molecular evaluation of antibiotic susceptibility of <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in axenic medium. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">55</emphasis><emphasis role="strong">:</emphasis>178–181.</para>
          </listitem>
          <listitem id="ch0087s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Masselot F, Boulos A, Maurin M, Rolain JM, Raoult D.</emphasis> 2003. Molecular evaluation of antibiotic susceptibility: <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> paradigm. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1658–1664.</para>
          </listitem>
          <listitem id="ch0087s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Cannon WR.</emphasis> 2003. Whipple’s disease, genomics, and drug therapy. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">361:</emphasis>1916.</para>
          </listitem>
          <listitem id="ch0087s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Fenollar F, Perreal C, Raoult D.</emphasis> 2014. <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> natural resistance to trimethoprim and sulphonamides <citetitle><emphasis>in vitro. Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">43</emphasis><emphasis role="strong">:</emphasis>388–390.</para>
          </listitem>
          <listitem id="ch0087s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Feurle GE, Junga NS, Marth T.</emphasis> 2010. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple’s disease. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">138</emphasis><emphasis role="strong">:</emphasis>478–486.</para>
          </listitem>
          <listitem id="ch0087s000000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Marth T.</emphasis> 2016. Whipple’s disease. <citetitle><emphasis>Acta Clin Belg</emphasis></citetitle> <emphasis role="strong">71</emphasis><emphasis role="strong">:</emphasis>373–378.</para>
          </listitem>
          <listitem id="ch0087s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Biagi F, Biagi GL, Corazza GR.</emphasis> 2017. What is the best therapy for Whipple’s disease? Our point of view. <citetitle><emphasis>Scand J Gastroenterol</emphasis></citetitle> <emphasis role="strong">52</emphasis><emphasis role="strong">:</emphasis>465–466.</para>
          </listitem>
          <listitem id="ch0087s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Lagier JC, Fenollar F, Lepidi H, Giorgi R, Million M, Raoult D.</emphasis> 2014. Treatment of classic Whipple’s disease: from in vitro results to clinical outcome. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">69</emphasis><emphasis role="strong">:</emphasis>219–227.</para>
          </listitem>
          <listitem id="ch0087s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Lagier JC, Fenollar F, Lepidi H, Raoult D.</emphasis> 2011. Evidence of lifetime susceptibility to <citetitle><emphasis>Tropheryma whipplei</emphasis></citetitle> in patients with Whipple’s disease. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1188–1189.</para>
          </listitem>
          <listitem id="ch0087s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Feurle GE, Moos V, Schinnerling K, Geelhaar A, Allers K, Biagi F, Bläker H, Moter A, Loddenkemper C, Jansen A, Schneider T.</emphasis> 2010. The immune reconstitution inflammatory syndrome in whipple disease: a cohort study. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">153</emphasis><emphasis role="strong">:</emphasis>710–717.</para>
          </listitem>
          <listitem id="ch0087s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Schneider T, Stallmach A, von Herbay A, Marth T, Strober W, Zeitz M.</emphasis> 1998. Treatment of refractory Whipple disease with interferon-gamma. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">129</emphasis><emphasis role="strong">:</emphasis>875–877.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
